Cite
Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.
MLA
Jie Shen, et al. “Multicenter, Single-Arm, Phase II Study (CAP) of Radiotherapy plus Liposomal Irinotecan Followed by Camrelizumab and Anti-Angiogenic Treatment in Advanced Solid Tumors.” Frontiers in Immunology, vol. 14, Mar. 2023, pp. 1–10. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1133689.
APA
Jie Shen, Jing Yan, Juan Du, Xiaoqin Li, Jia Wei, Qin Liu, Hongmei Yong, Xiaolu Wang, Xiaofeng Chang, Zhou Ding, Wu Sun, Chenxi Liu, Sihui Zhu, Jingyi Guo, Huajun Li, Ying Liu, Wulou Zhang, Zonghang Liu, Rutian Li, & Baorui Liu. (2023). Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors. Frontiers in Immunology, 14, 1–10. https://doi.org/10.3389/fimmu.2023.1133689
Chicago
Jie Shen, Jing Yan, Juan Du, Xiaoqin Li, Jia Wei, Qin Liu, Hongmei Yong, et al. 2023. “Multicenter, Single-Arm, Phase II Study (CAP) of Radiotherapy plus Liposomal Irinotecan Followed by Camrelizumab and Anti-Angiogenic Treatment in Advanced Solid Tumors.” Frontiers in Immunology 14 (March): 1–10. doi:10.3389/fimmu.2023.1133689.